Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules

PURPOSE: To identify sunitinib alternative schedules (AS) that maintained dose intensity while decreasing adverse events (AEs) in patients with metastatic renal cell cancer (mRCC), and to determine impact of AS on clinical outcomes. PATIENTS AND METHODS: A retrospective review of patients ≥ 18 yr of...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Atkinson, Bradley J., Kalra, Sarathi, Wang, Xuemei, Bathala, Tharakeswara, Corn, Paul, Tannir, Nizar M., Jonasch, Eric
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015627/
https://ncbi.nlm.nih.gov/pubmed/24018239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2013.08.090
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items